Generation Bio Co.

NasdaqGS:GBIO Voorraadrapport

Marktkapitalisatie: US$147.5m

Generation Bio Beheer

Beheer criteriumcontroles 3/4

De CEO Generation Bio is Geoff McDonough, benoemd in Oct2017, heeft een ambtstermijn van 7.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.32M, bestaande uit 27.2% salaris en 72.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.76% van de aandelen van het bedrijf, ter waarde $ 4.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 6.9 jaar.

Belangrijke informatie

Geoff McDonough

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris27.2%
Dienstverband CEO7.1yrs
Eigendom CEO2.8%
Management gemiddelde ambtstermijn3.5yrs
Gemiddelde ambtstermijn bestuur6.9yrs

Recente managementupdates

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11
Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14
Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Generation Bio EPS misses by $0.01

Nov 10

Analyse CEO-vergoeding

Hoe is Geoff McDonough's beloning veranderd ten opzichte van Generation Bio's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$630k

-US$127m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$134m

Dec 31 2022US$4mUS$606k

-US$137m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$6mUS$583k

-US$119m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$101m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$2mUS$516k

-US$81m

Sep 30 2020n/an/a

-US$72m

Jun 30 2020n/an/a

-US$68m

Mar 31 2020n/an/a

-US$65m

Dec 31 2019US$593kUS$424k

-US$61m

Compensatie versus markt: De totale vergoeding ($USD 2.32M ) Geoff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Geoff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Geoff McDonough (54 yo)

7.1yrs

Tenure

US$2,315,263

Compensatie

Dr. Cameron Geoffrey McDonough, also known as Geoff, M.D. serves as Independent Director of Third Harmonic Bio, Inc. since March 2024. He had been an Independent Director of Surface Oncology, Inc. since Fe...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Cameron McDonough
President7.1yrsUS$2.32m2.76%
$ 4.1m
Matthew Norkunas
Chief Financial Officer4.3yrsUS$1.14m0.086%
$ 126.7k
Matthew Stanton
Chief Scientific Officer5.5yrsUS$1.15m0.37%
$ 546.6k
Yalonda Howze
Chief Legal Officer & Secretary1.6yrsUS$1.21m0.021%
$ 31.4k
Mark Angelino
Co-Founder8.1yrsgeen gegevensgeen gegevens
Robert Kotin
Co-Founderno datageen gegevensgeen gegevens
Antoinette Paone
Chief Operating Officer2.8yrsgeen gegevens0.024%
$ 35.5k
Jasmin Tower
Chief Human Resources Officer1.7yrsgeen gegevensgeen gegevens
Phillip Samayoa
Chief Strategy Officer2.2yrsgeen gegevens0.18%
$ 269.8k

3.5yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Cameron McDonough
President7.1yrsUS$2.32m2.76%
$ 4.1m
Jason Rhodes
Independent Chairman7.1yrsUS$181.21k0%
$ 0
Gustav Christensen
Independent Director6.9yrsUS$143.71k0.20%
$ 290.4k
Charles Rowland
Independent Director6.3yrsUS$151.21k0.80%
$ 1.2m
Anthony Quinn
Independent Director6.9yrsUS$143.71k0.24%
$ 356.5k
Andrew Scharenberg
Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
Donald Nicholson
Independent Director6.9yrsUS$143.71k0.32%
$ 472.0k
Kevin Fitzgerald
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Adrian Thrasher
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Ronald H. Cooper
Independent Director3.7yrsUS$144.21k0.014%
$ 21.0k
Catherine Stehman-Breen
Independent Director6.9yrsUS$143.71k0.071%
$ 105.0k
Richard Thompson
Member of Scientific Advisory Board6.1yrsgeen gegevensgeen gegevens

6.9yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).